The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b/2 study of intratumoral Ad-RTS-hIL-12 + veledimex in patients with chemotherapy-responsive locally advanced or metastatic breast cancer.
 
Heather L. McArthur
Consulting or Advisory Role - Celgene; Merck; Spectrum Pharmaceuticals; Syndax
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Peregrine Pharmaceuticals (Inst); ZIOPHARM Oncology (Inst)
Travel, Accommodations, Expenses - Merck; Spectrum Pharmaceuticals
 
David B. Page
Consulting or Advisory Role - Celgene
Research Funding - MedImmune (Inst); Merck
Travel, Accommodations, Expenses - MedImmune
 
Tracy Ann Proverbs-Singh
No Relationships to Disclose
 
Stephen Barnett Solomon
Leadership - Devicor Medical Products
Stock and Other Ownership Interests - Aspire Bariatrics; Johnson & Johnson; Progenics
Consulting or Advisory Role - AngioDynamics; Covidien; GE Healthcare
Research Funding - AngioDynamics (Inst); GE Healthcare (Inst)
Patents, Royalties, Other Intellectual Property - Aspire Bariatrics; GE Healthcare-patents pending (Inst)
 
Clifford A. Hudis
Other Relationship - Breast Cancer Research Foundation
 
Larry Norton
No Relationships to Disclose
 
Sujata Patil
No Relationships to Disclose
 
John A Barrett
Employment - ZIOPHARM Oncology
Stock and Other Ownership Interests - ZIOPHARM Oncology
 
Francois M. Lebel
Employment - ZIOPHARM Oncology
Leadership - ZIOPHARM Oncology
Stock and Other Ownership Interests - ZIOPHARM Oncology